SGLT2 inhibition with empagliflozin attenuates myocardial oxidative stress and fibrosis in diabetic mice heart

SGLT2 inhibition with empagliflozin attenuates myocardial oxidative stress and fibrosis in diabetic mice heart

Abstract Background Hyperglycaemia associated with myocardial oxidative stress and fibrosis is the main cause of diabetic cardiomyopathy. Empagliflozin, a sodium-glucose cotransporter 2 (SGLT2) inhibitor has recently been reported to improve glycaemic control in patients with type 2 diabetes in an i...

Full description

Bibliographic Details
Main Authors:	Chenguang Li, Jie Zhang, Mei Xue, Xiaoyu Li, Fei Han, Xiangyang Liu, Linxin Xu, Yunhong Lu, Ying Cheng, Ting Li, Xiaochen Yu, Bei Sun, Liming Chen
Format:	Article
Language:	English
Published:	BMC 2019-02-01
Series:	Cardiovascular Diabetology
Subjects:	Type 2 diabetes mellitus SGLT2 Empagliflozin Oxidative stress Myocardial fibrosis
Online Access:	http://link.springer.com/article/10.1186/s12933-019-0816-2

Similar Items

The Association of SGLT-2 inhibitors (Empagliflozin) with the development of hypernatremic dehydration: a case report
by: Diana Alegre-González, et al.
Published: (2025-10-01)

The sodium–glucose co-transporter 2 inhibitor empagliflozin attenuates cardiac fibrosis and improves ventricular hemodynamics in hypertensive heart failure rats
by: Hsiang-Chun Lee, et al.
Published: (2019-04-01)

SGLT2 inhibitors and the changing landscape for treatment of diabetes
by: Liu S, et al.
Published: (2019-07-01)

Effects of SGLT2 inhibition via empagliflozin on cognitive and physical impairment in frail diabetic elders with chronic kidney disease
by: Pasquale Mone, et al.
Published: (2024-02-01)

Empagliflozin Inhibits Hepatic Gluconeogenesis and Increases Glycogen Synthesis by AMPK/CREB/GSK3β Signalling Pathway
by: Xiaochen Yu, et al.
Published: (2022-03-01)

Effects of Empagliflozin on Myocardial Flow Reserve in Patients With Type 2 Diabetes Mellitus: The SIMPLE Trial
by: Mikkel Jürgens, et al.
Published: (2021-08-01)

Empagliflozin: a potential anticancer drug
by: Wenwen Wu, et al.
Published: (2023-07-01)

Effects of empagliflozin on reproductive system in men without diabetes
by: Christophe Kosinski, et al.
Published: (2024-06-01)

Comparison of Extraglycemic effects of Dapagliflozin and Empagliflozin
by: Haroon Aziz, et al.
Published: (2023-06-01)

Protease XIV abolishes NHE inhibition by empagliflozin in cardiac cells
by: Sha Chen, et al.
Published: (2023-07-01)

[Budget impact analysis of empagliflozin for the treatment of type 2 diabetes in Italy]
by: Sergio Iannazzo, et al.
Published: (2016-03-01)

Acute and Chronic Effects of SGLT2 Inhibitor Empagliflozin on Renal Oxygenation and Blood Pressure Control in Nondiabetic Normotensive Subjects: A Randomized, Placebo‐Controlled Trial
by: Anne Zanchi, et al.
Published: (2020-07-01)

Empagliflozin: a wonder drug for the treatment of SIAD?
by: Ploutarchos Tzoulis
Published: (2024-10-01)

Empagliflozin in type 1 diabetes
by: Mathieu C, et al.
Published: (2019-08-01)

Navigating the therapeutic landscape of SGLT2 inhibitors in diabetes management: exploring efficacy and emerging concerns
by: Farazul Hoda, et al.
Published: (2024-11-01)

Structural repurposing of SGLT2 inhibitor empagliflozin for strengthening anti-heart failure activity with lower glycosuria
by: Yixiang Xu, et al.
Published: (2023-04-01)

Empagliflozin reduces diffuse myocardial fibrosis by extracellular volume mapping: A meta-analysis of clinical studies
by: Haipeng Wang, et al.
Published: (2022-08-01)

The role of SGLT2i in attenuating residual cardiovascular risk through blood pressure-lowering: mechanistic insights and perspectives
by: Joaquim Barreto, et al.
Published: (2023-09-01)

Empagliflozin Alleviates Atherosclerosis Progression by Inhibiting Inflammation and Sympathetic Activity in a Normoglycemic Mouse Model
by: Liu Y, et al.
Published: (2021-05-01)

Impact of empagliflozin on subclinical left ventricular dysfunctions and on the mechanisms involved in myocardial disease progression in type 2 diabetes: rationale and design of the EMPA-HEART trial
by: Andrea Natali, et al.
Published: (2017-10-01)

Comparative Efficacy of Dapagliflozin and Empagliflozin of a Fixed Dose in Heart Failure: A Network Meta-Analysis
by: Zepeng Shi, et al.
Published: (2022-04-01)

Comparing and Contrasting the Effects of the SGLT Inhibitors Canagliflozin and Empagliflozin on the Progression of Retinopathy
by: Lakshini Y. Herat, et al.
Published: (2023-04-01)

Case Report: Diabetic ketoacidosis after co-administration of empagliflozin and probenecid [version 2; peer review: 2 approved, 1 approved with reservations]
by: Niamh Reidy, et al.
Published: (2024-03-01)

Empagliflozin: a new strategy for nephroprotection in diabetes
by: Anton Ivanovich Korbut, et al.
Published: (2017-05-01)

Association between Empagliflozin Use and Electrocardiographic Changes
by: Daniel Antwi-Amoabeng, et al.
Published: (2022-07-01)

Mediators of the improvement in heart failure outcomes with empagliflozin in the EMPA‐REG OUTCOME trial
by: David Fitchett, et al.
Published: (2021-12-01)

Short-Term Treatment with Empagliflozin Resulted in Dehydration and Cardiac Arrest in an Elderly Patient with Specific Complications: A Case Report and Literature Review
by: Sopak Supakul, et al.
Published: (2022-06-01)

Empagliflozin Prevents Worsening of Cardiac Function in an Experimental Model of Pressure Overload-Induced Heart Failure
by: Nikole J. Byrne, BSc, et al.
Published: (2017-08-01)

Fournier’s gangrene in recent transplant recipient on empagliflozin
by: Lisa M. Raven, MBBS, FRACP, et al.
Published: (2024-05-01)

The impact of empagliflozin on cardiac physiology and fibrosis early after myocardial infarction in non-diabetic rats
by: Elias Daud, et al.
Published: (2021-07-01)

Empagliflozin suppresses mitochondrial reactive oxygen species generation and mitigates the inducibility of atrial fibrillation in diabetic rats
by: Takuya Koizumi, et al.
Published: (2023-02-01)

Sodium-Glucose Cotransporter-2 (SGLT2) Inhibitors: A Clinician’s Guide
by: Simes BC, et al.
Published: (2019-10-01)

Effects of Empagliflozin and Dapagliflozin in alleviating cardiac fibrosis through SIRT6-mediated oxidative stress reduction
by: Hong-xia Ma, et al.
Published: (2024-12-01)

Empagliflozin-associated postoperative mixed metabolic acidosis. Case report and review of pathogenesis
by: Michal Sitina, et al.
Published: (2023-04-01)

Effect of Empagliflozin Treatment on Ventricular Repolarization Parameters
by: Fatih Ozturk, et al.
Published: (2024-02-01)

Empagliflozin Alleviates Hepatic Steatosis by Activating the AMPK-TET2-Autophagy Pathway in vivo and in vitro
by: Ting Li, et al.
Published: (2021-01-01)

Empagliflozin’s role in early tubular protection for type 2 diabetes patients
by: Chuangbiao Zhang, et al.
Published: (2024-07-01)

SGLT2 Inhibitors in Management of Severe Hypomagnesemia in Patients Without Diabetes: A Report of 4 Cases
by: Chintan V. Shah, et al.
Published: (2023-09-01)

SGLT2 Inhibition in Acute Myocardial Infarction—A Comprehensive Review
by: Martin Benedikt, et al.
Published: (2023-01-01)

Empagliflozin Use and Fournier’s Gangrene: Case Report and Systematic Literature Review
by: Mario Antunes, et al.
Published: (2021-05-01)